SCHEMBL4329288

SCHEMBL4329288

NC(=S)N(CCN1CCCC1)N=Cc1ccc(-c2ccc(Cl)c(Cl)c2)o1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 9/20 0.52
ALDH1A1 P00352 8/20 0.52
KMT2A Q03164 7/20 0.52
MAPT P10636 7/20 0.52
MEN1 O00255 6/20 0.52
NPSR1 Q6W5P4 3/20 0.52
HTT P42858 1/20 0.52
HSD17B10 Q99714 3/20 0.43
PKM P14618 3/20 0.43
USP2 O75604 2/20 0.43
ALOX15 P16050 2/20 0.43
KDM4E B2RXH2 4/20 0.40
GAA P10253 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPK1 P28482 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4329284 1.00 HPGD (0.52) HPGDALDH1A1KMT2AMAPTMEN1
SCHEMBL4326666 0.99 HPGD (0.51) HPGDALDH1A1KMT2AMAPTMEN1
SCHEMBL4341232 0.85 KMT2A (0.58) HPGDALDH1A1KMT2AMAPTMEN1
SCHEMBL4331665 0.83 KMT2A (0.56) HPGDALDH1A1KMT2AMAPTMEN1
SCHEMBL4331661 0.83 KMT2A (0.56) HPGDALDH1A1KMT2AMAPTMEN1
SCHEMBL4324411 0.81 KDM4E (0.50) HPGDALDH1A1KMT2AMAPTMEN1
SCHEMBL4324406 0.81 KDM4E (0.50) HPGDALDH1A1KMT2AMAPTMEN1
SCHEMBL4455856 0.81 KMT2A (0.60) HPGDALDH1A1KMT2AMAPTMEN1
SCHEMBL13887398 0.81 KMT2A (0.57) HPGDALDH1A1KMT2AMAPTMEN1
SCHEMBL4329090 0.80 ALDH1A1 (0.52) HPGDALDH1A1KMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 HPGD 1646/4885ALDH1A1 1459/4885KMT2A 3988/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 HPGD 1495/4885ALDH1A1 1173/4885KMT2A 3714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.